FGF21 analogs (efruxifermin / pegozafermin / efimosfermin)
Metabolic Health · FGF21 analog / MASH pipeline
Tier C+
What this is
Promoted from watchlist because the class now has several named, active Phase 3 MASH programs plus peer-reviewed Phase 2b human data. Efruxifermin HARMONY 96-week results showed sustained histologic MASH/fibrosis signal; pegozafermin ENLIVEN showed NASH/MASH improvements and large triglyceride/liver-fat effects; efimosfermin alfa has Phase 2a data and Phase 3 trials recruiting. Still an investigational liver-disease class, not a general longevity drug. Industry-funded trials; clinical outcomes and long-term safety pending.
Mechanism
Long-acting fibroblast growth factor 21 analogs activate FGFR1c/β-Klotho signaling to improve hepatic fat metabolism, insulin sensitivity, triglycerides, adiponectin, and liver inflammation/fibrosis biology.
Dose & route
Weekly or every-2-week SC injection in trials: efruxifermin 28-50 mg weekly; pegozafermin 15-30 mg weekly or 44 mg Q2W; efimosfermin alfa trial dosing varies
Citations
- https://pubmed.ncbi.nlm.nih.gov/40818852/
- https://pubmed.ncbi.nlm.nih.gov/37356033/
- https://pubmed.ncbi.nlm.nih.gov/40484014/
- https://clinicaltrials.gov/study/NCT06318169
- https://clinicaltrials.gov/study/NCT07221227
Links go to the source. If a link is dead or you want something re-checked, let me know.
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.